Total Payments
$144,807
2024 Payments
$26,780
Companies
30
Transactions
393
Medicare Patients
17,958
Medicare Billing
$11.6M
Payment Breakdown by Category
Consulting$89,120 (61.5%)
Food & Beverage$16,310 (11.3%)
Other$16,159 (11.2%)
Travel$15,359 (10.6%)
Research$7,662 (5.3%)
Education$107.77 (0.1%)
Gifts$88.97 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $89,120 | 29 | 61.5% |
| Food and Beverage | $16,310 | 313 | 11.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,822 | 7 | 10.9% |
| Travel and Lodging | $15,359 | 31 | 10.6% |
| Unspecified | $7,662 | 6 | 5.3% |
| Honoraria | $336.65 | 3 | 0.2% |
| Education | $107.77 | 2 | 0.1% |
| Gift | $88.97 | 2 | 0.1% |
Payments by Type
General
$137,145
387 transactions
Research
$7,662
6 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Genentech, Inc. | $35,354 | 72 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $28,487 | 34 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $18,297 | 61 | $0 (2024) |
| F. Hoffmann-La Roche AG | $13,768 | 8 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $13,205 | 10 | $0 (2024) |
| Genentech USA, Inc. | $10,340 | 100 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $8,555 | 13 | $0 (2021) |
| Carl Zeiss Meditec, Inc. | $4,892 | 5 | $0 (2023) |
| Allergan, Inc. | $4,345 | 23 | $0 (2021) |
| ABBVIE INC. | $2,148 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $26,780 | 75 | Regeneron Healthcare Solutions, Inc. ($14,764) |
| 2023 | $30,263 | 63 | Regeneron Pharmaceuticals, Inc. ($8,799) |
| 2022 | $22,613 | 34 | Apellis Pharmaceuticals, Inc. ($21,334) |
| 2021 | $1,589 | 21 | Allergan, Inc. ($766.35) |
| 2020 | $3,674 | 14 | F. Hoffmann-La Roche AG ($2,366) |
| 2019 | $23,355 | 50 | Novartis Pharmaceuticals Corporation ($8,452) |
| 2018 | $9,363 | 54 | Genentech, Inc. ($7,254) |
| 2017 | $27,171 | 82 | Genentech, Inc. ($14,857) |
All Payment Transactions
393 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/24/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,116.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/16/2024 | Sandoz Inc. | Cimerli (Biological) | Food and Beverage | In-kind items and services | $34.65 | General |
| Category: Ophthalmology | ||||||
| 12/05/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $47.82 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 12/03/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $115.08 | General |
| Category: Ophthalmology | ||||||
| 12/02/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $28.79 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/19/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $18.41 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/11/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $68.39 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/09/2024 | Genentech USA, Inc. | Susvimo (Drug), Vabysmo | Food and Beverage | In-kind items and services | $122.82 | General |
| Category: Immunology and Ophthalmology | ||||||
| 11/08/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $192.18 | General |
| Category: Ophthalmology | ||||||
| 11/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $22.83 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/05/2024 | Astellas Pharma US Inc | Izervay (Drug) | Food and Beverage | In-kind items and services | $24.86 | General |
| Category: Ophthalmology | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,703.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/29/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $21.83 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/22/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $19.78 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/19/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $107.39 | General |
| Category: Immunology and Ophthalmology | ||||||
| 10/15/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $28.40 | General |
| Category: EYE CARE | ||||||
| 10/09/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Food and Beverage | In-kind items and services | $16.90 | General |
| Category: Ophthalmology | ||||||
| 10/01/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological), EYLEA | Food and Beverage | In-kind items and services | $130.35 | General |
| Category: OPHTHALMOLOGY | ||||||
| 09/30/2024 | F. Hoffmann-La Roche AG | — | — | In-kind items and services | $685.13 | Research |
| Study: VA2 PhIII | ||||||
| 09/18/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $20.94 | General |
| Category: Immunology and Ophthalmology | ||||||
| 09/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/26/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $108.75 | General |
| Category: Immunology and Ophthalmology | ||||||
| 08/26/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $26.49 | General |
| Category: OPHTHALMOLOGY | ||||||
| 08/14/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $22.56 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/31/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: Immunology and Ophthalmology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| STAIRWAY SIMULTANEOUS BLOCKADE OF ANGIOPOIETIN-2 AND VEGF-A WITH THE BISPECIFIC ANTIBODY RO6867461 RG7716 FOR EXTENDED DURABILITY IN THE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | F. Hoffmann-La Roche AG | $2,366 | 1 |
| New Findings of Faricimab for Diabetic Macular Edema | F. Hoffmann-La Roche AG | $2,192 | 1 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $1,729 | 1 |
| VA2 PhIII | F. Hoffmann-La Roche AG | $895.76 | 2 |
| Biomarkers for Vascular Stability, Including Inflammation, and Fibrosis, Demonstrate the Benefit of Dual Ang-2/VEGF-A Inhibition With Faricimab in Phase 3 Trials in DME | F. Hoffmann-La Roche AG | $479.55 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 25 | 4,782 | 36,509 | $9.8M | $3.1M |
| 2022 | 19 | 4,320 | 16,149 | $8.9M | $2.6M |
| 2021 | 19 | 4,235 | 14,603 | $9.7M | $2.9M |
| 2020 | 14 | 4,621 | 15,699 | $9.9M | $3.0M |
Total Patients
17,958
Total Services
82,960
Medicare Billing
$11.6M
Procedure Codes
77
All Medicare Procedures & Services
77 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 210 | 1,668 | $3.3M | $1.2M | 34.6% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 67 | 23,760 | $1.7M | $683,349 | 41.3% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 88 | 1,233 | $986,400 | $267,768 | 27.1% |
| J3490 | Unclassified drugs | Office | 2023 | 51 | 116 | $472,000 | $210,436 | 44.6% |
| 67028 | Injection of drug into eye | Office | 2023 | 386 | 1,521 | $1.1M | $170,065 | 15.6% |
| 92134 | Imaging of retina | Office | 2023 | 1,031 | 2,779 | $472,430 | $100,983 | 21.4% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 39 | 795 | $238,500 | $95,687 | 40.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 695 | 1,094 | $328,200 | $86,471 | 26.3% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 55 | 431 | $344,800 | $80,172 | 23.3% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 350 | 623 | $155,750 | $49,842 | 32.0% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 291 | 362 | $162,900 | $38,883 | 23.9% |
| Q5124 | Injection, ranibizumab-nuna, biosimilar, (byooviz), 0.1 mg | Office | 2023 | 15 | 140 | $112,000 | $24,759 | 22.1% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 22 | 22 | $143,000 | $23,603 | 16.5% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 532 | 759 | $68,310 | $16,331 | 23.9% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 80 | 80 | $36,000 | $11,810 | 32.8% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 90 | 90 | $40,500 | $11,718 | 28.9% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 63 | 64 | $19,200 | $8,060 | 42.0% |
| 92202 | Extended exam of the back part of the eye with optic nerve drawing | Office | 2023 | 385 | 569 | $48,365 | $7,679 | 15.9% |
| 92250 | Photography of the retina | Office | 2023 | 171 | 219 | $38,325 | $7,326 | 19.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 55 | 57 | $19,950 | $6,589 | 33.0% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 21 | 24 | $37,500 | $5,129 | 13.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 36 | 36 | $10,800 | $3,481 | 32.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 24 | 34 | $6,630 | $1,538 | 23.2% |
| 76510 | 1d and 2d ultrasound scan of eye tissue and structures | Office | 2023 | 13 | 17 | $5,100 | $1,114 | 21.8% |
| 92020 | Exam of the internal drainage system of eye | Office | 2023 | 12 | 16 | $1,200 | $411.84 | 34.3% |
About Dr. Philip Ferrone, MD
Dr. Philip Ferrone, MD is a Ophthalmology healthcare provider based in Great Neck, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1164535472.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Ferrone, MD has received a total of $144,807 in payments from pharmaceutical and medical device companies, with $26,780 received in 2024. These payments were reported across 393 transactions from 30 companies. The most common payment nature is "Consulting Fee" ($89,120).
As a Medicare-enrolled provider, Ferrone has provided services to 17,958 Medicare beneficiaries, totaling 82,960 services with total Medicare billing of $11.6M. Data is available for 4 years (2020–2023), covering 77 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Great Neck, NY
- Active Since 08/17/2006
- Last Updated 10/08/2021
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1164535472
Products in Payments
- Non-Covered Product (Drug) $27,215
- EYLEA HD (Biological) $22,949
- Lucentis (Biological) $14,238
- BEOVU (Drug) $8,465
- EYLEA (Biological) $8,185
- Vabysmo (Drug) $7,105
- SYFOVRE (Drug) $5,430
- OZURDEX (Drug) $4,432
- FORUM (Device) $3,750
- Syfovre (Drug) $1,110
- VISULAS 532s (Device) $1,000
- Cimerli (Biological) $566.37
- EYLEA AFLIBERCEPT INJECTION (Biological) $226.67
- Constellation (Device) $129.14
- COMBIGAN (Drug) $123.48
- Susvimo (Drug) $122.82
- OXERVATE (Drug) $120.06
- Rhopressa (Drug) $119.24
- YUTIQ (Drug) $96.34
- VABYSMO (Drug) $81.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Great Neck
Dr. Jonathan Jonisch, Md, MD
Ophthalmology — Payments: $622,818
Ophthalmology $622,818
Kenneth Rosenthal, Md, MD
Ophthalmology — Payments: $72,719
Ophthalmology $72,719
Dr. David Rhee, Md, MD
Ophthalmology — Payments: $13,182
Ophthalmology $13,182
George Tung, Md, MD
Ophthalmology — Payments: $7,576
Ophthalmology $7,576
Juan Romero, Md, MD
Ophthalmology — Payments: $6,910
Ophthalmology $6,910
Richard Russell, M.d, M.D
Ophthalmology — Payments: $5,822
Ophthalmology $5,822